Tricuspid Regurgitation in Atrial Fibrillation: Incidence, Burden, and Clinical Impact

Tricuspid regurgitation is a condition commonly found in people who have been suffering from atrial fibrillation for quite some time now. As the atria of the right side of the heart dilate, the tricuspid valve ring becomes stretched and causes the valve flaps to fail in closing. In such cases, even though there is no abnormality with the flaps of the valve itself, blood still leaks backwards at every heartbeat. Since all these events occur gradually, they are easily overlooked by the patient himself, and may even go unnoticed, and even if noticed, might be misinterpreted as something else, resulting in a diagnosis of fatigue, inability to exercise or slight swelling in the legs.

Why It Matters

Tricuspid regurgitation (TR) means the valve between the right atrium and ventricle leaks, letting blood flow backward each heartbeat. In atrial fibrillation, this leak is usually due to a functional issue. Years of irregular rhythm cause the right atrium to expand and the valve ring to dilate. The valve leaflets are still intact, but they fail to meet and seal. This is different from valve disease caused by infection or leaflet damage. A functional problem like this can hide for years, so many patients aren’t diagnosed until they develop clear right-sided heart failure symptoms. For example, by the time a patient has obvious leg swelling or belly bloating, the TR may already be severe. In its early stages, the symptoms are not very noticeable. Mild and moderate cases of TR cause an increased sense of tiredness and difficulty exercising. Others might experience minor swelling in their ankles and the sensation of bloating. These symptoms may be attributed to the natural process of getting older or other diseases. However, with the progression of TR, patients will experience severe failure of the right ventricle: large swelling in the ankles, ascites, engorged liver, and extreme fatigue. This is usually accompanied by increased visits to hospitals and greater dependence on diuretics. Physicians whose specialization lies in the left ventricle often overlook these symptoms.

As AF becomes more common, TR becomes more common. An aging population means more AF, and more AF over time means more patients at risk of tricuspid valve issues. Clinicians are performing more echocardiograms and scheduling more cardiology appointments to catch these problems. Hospitals see a rising demand for cardiologists who manage valve disease. At the same time, new catheter-based treatments for TR are emerging, but robust evidence for their use is still limited. Health systems now must balance the costs of increased testing and procedures with the potential benefits of preventing repeated heart failure hospitalizations downstream.

Who It Affects

Long-standing AF is the main risk factor. Patients who have had atrial fibrillation for many years are at highest risk for developing TR. The risk is especially high in older adults and in people whose AF is persistent or permanent rather than paroxysmal. When the right atrium remains enlarged for a long time, the tricuspid valve is more likely to leak.

Other conditions also play a role. Chronic lung diseases like COPD or pulmonary fibrosis can put extra pressure on the right heart and accelerate TR. Sometimes a pacemaker or defibrillator lead crosses the tricuspid valve on its way to the right ventricle. In some patients, these leads can tangle with the valve leaflets and worsen leakage. In summary, chronic AF combined with right-heart strain significantly raises the chance of TR.

Various experts become involved. The electrophysiologist takes care of the pacing; for instance, using drugs or ablation for the pacing issue, which will eventually result in normalization of the pacing and hence reduction in size of the atria. The heart failure specialists will address the issues associated with fluid buildup through the use of diuretics. The imaging specialists will be instrumental in detecting TR early enough and monitoring it throughout the process. The interventional cardiology and cardiac surgery specialists take care of severe cases of TR repair and replacement.

The healthcare system feels it too. Greater recognition of AF-related TR means more echocardiograms and more specialist visits. If transcatheter tricuspid interventions become routine, hospitals will need specialized structural heart teams. In contrast, if the issue is ignored, patients may end up sicker and far more expensive to care for. People with advanced TR often have multiple hospitalizations and disability. Early diagnosis and coordinated care can help avoid these costs.

What Changes

• Screening and early detection:If a patient with AF complains of new swelling in the legs, fatigue, or abdominal swelling, the right side of the heart must be assessed. Requesting an echocardiography focusing on the dimensions of the right atrium, tricuspid annulus, and degree of regurgitation would help detect issues early on. This way, regurgitation is caught early when its treatment is easier.
• AF management through collaboration: It starts with achieving optimal AF management. This entails rhythm control using antiarrhythmic drugs or ablation techniques, which might help the right atrium to reduce in size. Simultaneously, fluid overload should be managed by diuretics and other treatments for heart failure. Electrophysiologists and cardiologists specializing in heart failure can help stabilize the situation of many patients and postpone surgery.
• Interventions if required: If the patient’s TR continues to deteriorate or the condition is already serious, it is vital to refer them for expert help at valve centers or heart teams. These experts will help determine whether surgery, valve replacement, or percutaneous intervention is ideal for the patient. There are new types of devices (for instance, transcatheter edge-to-edge TriClip/PASCAL clips or percutaneous annuloplasty rings) that are effective for high-risk patients. However, these interventions have some risk, and they do not necessarily cure the condition.
• Systems approach: The hospitals should establish care pathways that integrate electrophysiology services, heart failure programs, imaging facilities, and structural heart programs. In this case, any AF patient who is at risk of TR can be referred to all relevant specialists. Even insurance programs need to change to suit these needs, such as through offering coverage for advanced tricuspid imaging like three-dimensional ultrasound imaging and new catheter techniques when necessary. Outcome data will be collected using registries.

Clinical Decision-Making and Practical Considerations**

Look for right-sided clues: In practice, if a patient with AF has signs of fluid overload – such as puffy ankles, a swollen abdomen, or distended neck veins then clinicians should evaluate the right heart immediately. Listening for a holosystolic murmur at the left lower sternum or noting an enlarged liver can be clues. A quick bedside ultrasound of the tricuspid valve should be part of the assessment. These steps help catch TR early, long before severe symptoms appear.

Manage the rhythm to help the valve: Keeping the heart in normal rhythm whenever possible can reduce stress on the tricuspid valve. Successful AF ablation or medication control may let the right atrium shrink, potentially reducing annular dilation. This doesn’t cure all cases of TR, but it can improve symptoms and slow progression in some patients.

Timing is crucial: Don’t wait until end-stage heart failure to involve valve specialists. Referral for valve repair or replacement is most effective if done before irreversible damage occurs. If the right ventricle or the liver is already failing from chronic congestion, fixing the valve later may not restore full function. Ideally, involve a valve expert when TR first becomes more than mild or when symptoms emerge, rather than after major organ injury has happened.

Set realistic expectations: Have honest conversations with patients about new tricuspid treatments. Emphasize that while emerging procedures can improve symptoms and reduce leakage, they are not magical fixes. Discuss the potential benefits and risks, and clarify that patients may still need medical therapy and follow-up even after a procedure. Setting realistic goals and clear expectations helps patients engage in their care plan.

Policy and Research Gaps**

Evidence gaps: More research is required on TR due to AF. Which AF patients require early intervention? Is routine tricuspid evaluation mandatory in all AF patients? Prospective clinical trials and patient registries can provide answers to these questions. Meanwhile, health care practitioners must submit their cases in registries and make decisions according to available evidence using clinical discretion.

Policy gaps: On the policy side, coding and reimbursement for tricuspid care are still evolving. New procedures may lack clear billing codes or approval pathways. Payers and hospitals should develop policies that allow appropriate use of advanced tricuspid diagnostics and treatments. Additionally, training programs should emphasize right-heart imaging and intervention skills, since many cardiology curricula have historically focused more on the left heart.

Looking Ahead**

Clinician awareness is key: The immediate priority is recognizing that atrial fibrillation can lead to structural changes on the right side of the heart. Educators and professional groups should stress the importance of routinely checking right atrial size and tricuspid valve function in AF patients. Incorporating reminders or prompts in echo reports and clinic notes can keep this issue on clinicians’ radar and lead to earlier detection.

Planning now prevents crises later: Health systems and policymakers should plan for the growing need. This means funding research on AF and TR, developing dedicated valve clinics or programs, and creating clear referral networks between electrophysiology, heart failure, imaging, and structural heart teams. Investing in these now will prevent a scramble for resources when many patients need care.

Patient empowerment: Encourage patients to speak up about new symptoms. If someone has persistent AF and notices unexplained swelling in their legs, belly, or neck, they should mention it to their doctor. These signs may have nothing to do with the left heart or their lungs, but could be an early clue of a treatable tricuspid problem. Patients who speak up can get the right evaluation sooner.

Tricuspid regurgitation in atrial fibrillation sits at the crossroads of rhythm management, heart failure care, and valve disease. It is a condition that rewards early attention and coordinated care. As tools for diagnosis and treatment improve, aligning clinical teams and health systems now will turn a once-silent problem into one we handle proactively – keeping patients well instead of scrambling to rescue them.

References

1. Kwak, S., Lim, J., Yang, S., Rhee, T.-M., Choi, Y.-J., Lee, H.-J., et al. Atrial Functional Tricuspid Regurgitation: Importance of Atrial Fibrillation and Right Atrial Remodeling and Prognostic Significance. JACC: Cardiovascular Imaging. 2023.https://pubmed.ncbi.nlm.nih.gov/36669928/
2. Patlolla, S. H., Schaff, H. V., Nishimura, R. A., Stulak, J. M., Chamberlain, A. M., Pislaru, S. V., & Nkomo, V. T. Incidence and Burden of Tricuspid Regurgitation in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2022. https://pubmed.ncbi.nlm.nih.gov/36480971/
3. Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P. III, Gentile, F., et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000923
4. Romeo, J. D., Bashline, M. J., Fowler, J. A., Kliner, D. E., Toma, C., Smith, A. C., Sultan, I., & Sanon, S. Current Status of Transcatheter Tricuspid Valve Therapies. Heart International. 2022. https://pubmed.ncbi.nlm.nih.gov/36275351/